{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:10:34Z","timestamp":1792098634987,"version":"4.4.0"},"reference-count":121,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To describe the most common serious adverse effects and organ toxicities associated with emerging therapies for cancer that may necessitate admission to the ICU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources and Study Selection:<\/jats:title>\n                    <jats:p>PubMed and Medline search of relevant articles in English on the management of adverse effects of immunotherapy for cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Extraction and Data Synthesis:<\/jats:title>\n                    <jats:p>Targeted therapies including tyrosine kinase inhibitors, monoclonal antibodies, checkpoint inhibitors, and immune effector cell therapy have improved the outcome and quality of life of patients with cancer. However, severe and life-threatening side effects can occur. These toxicities include infusion or hypersensitivity reactions, cytokine release syndrome, pulmonary, cardiac, renal, hepatic, and neurologic toxicities, hemophagocytic lymphohistiocytosis, opportunistic infections, and endocrinopathies. Cytokine release syndrome is the most common serious toxicity after administration of monoclonal antibodies and immune effector cell therapies. Most of the adverse events from immunotherapy results from an exaggerated T-cell response directed against normal tissue, resulting in the generation of high levels of proinflammatory cytokines. Toxicities from targeted therapies are usually secondary to \u201con target toxicities.\u201d Management is largely supportive and may include discontinuation of the specific agent, corticosteroids, and other immune suppressing agents for severe (grade 3 or 4) immune-related adverse events like neurotoxicity and pneumonitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The complexity of toxicities associated with modern targeted and immunotherapeutic agents for cancer require a multidisciplinary approach among ICU staff, oncologists, and organ specialists and adoption of standardized treatment protocols to ensure the best possible patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ccm.0000000000004087","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T08:11:11Z","timestamp":1573719071000},"page":"10-21","source":"Crossref","is-referenced-by-count":73,"title":["Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer"],"prefix":"10.1097","volume":"48","author":[{"given":"Cristina","family":"Gutierrez","sequence":"first","affiliation":[{"name":"Department of Critical Care, The University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"McEvoy","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laveena","family":"Munshi","sequence":"additional","affiliation":[{"name":"Interdepartmental Division of Critical Care Medicine, Toronto General Hospital, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Stephens","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Detsky","sequence":"additional","affiliation":[{"name":"Interdepartmental Division of Critical Care Medicine, Mount Sinai Hospital, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Nates","sequence":"additional","affiliation":[{"name":"Division of Anesthesiology and Critical Care, Department of Critical Care, The University of Texas M.D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Pastores","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY."},{"name":"Departments of Medicine and Anesthesiology and Critical Care Medicine, Weill Cornell Medical College, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230812","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40264-013-0050-x","article-title":"Tyrosine kinase inhibitors: Their on-target toxicities as potential indicators of efficacy.","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"R3-20230812","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/neuonc\/nox115","article-title":"Neurological complications of new chemotherapy agents.","volume":"20","author":"Zukas","year":"2018","journal-title":"Neuro Oncol"},{"key":"R4-20230812","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaip.2016.12.001","article-title":"Current knowledge and management of hypersensitivity reactions to monoclonal antibodies.","volume":"5","author":"Picard","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R5-20230812","doi-asserted-by":"crossref","first-page":"e26333","DOI":"10.4161\/onci.26333","article-title":"Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.","volume":"2","author":"Baldo","year":"2013","journal-title":"Oncoimmunology"},{"key":"R6-20230812","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management.","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit Care"},{"key":"R7-20230812","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018.","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA"},{"key":"R8-20230812","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3390\/toxins6030914","article-title":"Immune checkpoint blockade in cancer treatment: A double-edged sword cross-targeting the host as an \u201cinnocent bystander.\u201d","volume":"6","author":"Gelao","year":"2014","journal-title":"Toxins (Basel)"},{"key":"R9-20230812","first-page":"317","article-title":"Complications of monoclonal antibody therapy.","volume":"94","author":"Meisel","year":"2011","journal-title":"Med Health R I"},{"key":"R10-20230812","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/mt.2014.148","article-title":"T-cell immunotherapy: Looking forward.","volume":"22","author":"Corrigan-Curay","year":"2014","journal-title":"Mol Ther"},{"key":"R11-20230812","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward.","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R12-20230812","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"R13-20230812","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells.","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"R14-20230812","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1097\/CCM.0000000000003258","article-title":"Management of the critically ill adult chimeric antigen receptor-T cell therapy patient: A critical care perspective.","volume":"46","author":"Gutierrez","year":"2018","journal-title":"Crit Care Med"},{"key":"R15-20230812","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma.","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"R16-20230812","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2217\/fon-2016-0005","article-title":"Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia.","volume":"12","author":"Asselin","year":"2016","journal-title":"Future Oncol"},{"key":"R17-20230812","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies.","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"R18-20230812","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/cti.2015.14","article-title":"Clinical development methodology for infusion-related reactions with monoclonal antibodies.","volume":"4","author":"Doessegger","year":"2015","journal-title":"Clin Transl Immunology"},{"key":"R19-20230812","doi-asserted-by":"crossref","first-page":"iv100","DOI":"10.1093\/annonc\/mdx216","article-title":"Management of infusion reactions to systemic anticancer therapy: ESMO clinical practice guidelines.","volume":"28","author":"Rosell\u00f3","year":"2017","journal-title":"Ann Oncol"},{"key":"R20-20230812","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/eci.09.31","article-title":"Monoclonal antibody-induced cytokine-release syndrome.","volume":"5","author":"Bugelski","year":"2009","journal-title":"Expert Rev Clin Immunol"},{"key":"R21-20230812","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1200\/JCO.2007.15.7883","article-title":"Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer.","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"key":"R22-20230812","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdf350","article-title":"Stevens-Johnson syndrome after treatment with rituximab.","volume":"13","author":"Lowndes","year":"2002","journal-title":"Ann Oncol"},{"key":"R23-20230812","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review.","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"R24-20230812","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"R25-20230812","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R26-20230812","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"R27-20230812","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas.","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"R28-20230812","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R29-20230812","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"key":"R30-20230812","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canlet.2013.10.004","article-title":"Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells.","volume":"343","author":"Xu","year":"2014","journal-title":"Cancer Lett"},{"key":"R31-20230812","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"R32-20230812","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome.","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"R33-20230812","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R34-20230812","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"R35-20230812","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"R36-20230812","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy.","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R37-20230812","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CMAR.S136818","article-title":"Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.","volume":"9","author":"Chuzi","year":"2017","journal-title":"Cancer Manag Res"},{"key":"R38-20230812","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1378\/chest.12-1467","article-title":"Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.","volume":"143","author":"Barjaktarevic","year":"2013","journal-title":"Chest"},{"key":"R39-20230812","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline.","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"R40-20230812","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy.","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"R41-20230812","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis.","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"R42-20230812","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab.","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R43-20230812","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"R44-20230812","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R45-20230812","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis.","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"R46-20230812","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1164\/rccm.201703-0548ST","article-title":"An official American Thoracic Society\/European Society of Intensive Care Medicine\/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical ventilation in adult patients with acute respiratory distress syndrome.","volume":"195","author":"Fan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R47-20230812","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccc.2009.10.001","article-title":"Acute respiratory failure in the patient with cancer: Diagnostic and management strategies.","volume":"26","author":"Pastores","year":"2010","journal-title":"Crit Care Clin"},{"key":"R48-20230812","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/ppul.20864","article-title":"Rituximab (B-cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature.","volume":"44","author":"Bitzan","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"R49-20230812","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s00277-018-3448-9","article-title":"Characteristics of pulmonary complications in non-Hodgkin\u2019s lymphoma patients treated with rituximab-containing chemotherapy and impact on survival.","volume":"97","author":"Keefer","year":"2018","journal-title":"Ann Hematol"},{"key":"R50-20230812","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","article-title":"Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.","volume":"32","author":"Medeiros","year":"2018","journal-title":"Blood Rev"},{"key":"R51-20230812","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ajh.24174","article-title":"Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.","volume":"90","author":"Shah","year":"2015","journal-title":"Am J Hematol"},{"key":"R52-20230812","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bcp.13508","article-title":"Dasatinib-induced pulmonary arterial hypertension.","volume":"84","author":"\u00d6zg\u00fcr Yurtta\u015f","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"R53-20230812","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-Associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer.","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol"},{"key":"R54-20230812","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/014107680710000501","article-title":"Connections with death.","volume":"100","author":"Abbasi","year":"2007","journal-title":"J R Soc Med"},{"key":"R55-20230812","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia.","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"R56-20230812","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11910-017-0785-3","article-title":"Neurological complications of therapeutic monoclonal antibodies: Trends from oncology to rheumatology.","volume":"17","author":"Gill","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R57-20230812","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"R58-20230812","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner.","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"R59-20230812","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature.","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"key":"R60-20230812","first-page":"2050313X18792422","article-title":"Atezolizumab-related encephalitis in the intensive care unit: Case report and review of the literature.","volume":"6","author":"Laserna","year":"2018","journal-title":"SAGE Open Med Case Rep"},{"key":"R61-20230812","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.","volume":"114","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"R62-20230812","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: Recognition and management.","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"R63-20230812","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial.","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"R64-20230812","first-page":"218","article-title":"Rituximab-induced polymorphic ventricular tachycardia.","volume":"37","author":"Poterucha","year":"2010","journal-title":"Tex Heart Inst J"},{"key":"R65-20230812","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2012-04-423079","article-title":"A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.","volume":"120","author":"Stopeck","year":"2012","journal-title":"Blood"},{"key":"R66-20230812","doi-asserted-by":"crossref","first-page":"e27987","DOI":"10.4161\/onci.27987","article-title":"Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of kounis syndrome.","volume":"3","author":"Kounis","year":"2014","journal-title":"Oncoimmunology"},{"key":"R67-20230812","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1515\/cclm-2016-0010","article-title":"Kounis syndrome: An update on epidemiology, pathogenesis, diagnosis and therapeutic management.","volume":"54","author":"Kounis","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"R68-20230812","first-page":"3735","article-title":"Attention to Infliximab adverse events: Chimeric monoclonal antibodies can induce anti chimeric antibodies that may result in Kounis hypersensitivity associated acute coronary syndrome.","volume":"18","author":"Kounis","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R69-20230812","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13256-017-1310-7","article-title":"Management of Kounis syndrome: Two case reports.","volume":"11","author":"Omri","year":"2017","journal-title":"J Med Case Rep"},{"key":"R70-20230812","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors.","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R71-20230812","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1634\/theoncologist.2018-0157","article-title":"Myocarditis associated with immune checkpoint inhibitors: An expert consensus on data gaps and a call to action.","volume":"23","author":"Neilan","year":"2018","journal-title":"Oncologist"},{"key":"R72-20230812","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia.","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"key":"R73-20230812","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/VHRM.S108874","article-title":"Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: Preventive strategies and cardiovascular surveillance.","volume":"13","author":"Aghel","year":"2017","journal-title":"Vasc Health Risk Manag"},{"key":"R74-20230812","doi-asserted-by":"crossref","first-page":"781","DOI":"10.21873\/anticanres.13175","article-title":"Cancer site and adverse events induced by immune checkpoint inhibitors: A retrospective analysis of real-life experience at a single institution.","volume":"39","author":"Sukari","year":"2019","journal-title":"Anticancer Res"},{"key":"R75-20230812","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: A narrative review.","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"R76-20230812","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"R77-20230812","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients.","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"R78-20230812","first-page":"300","article-title":"Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis.","volume":"2","author":"Jolly","year":"2009","journal-title":"NDT Plus"},{"key":"R79-20230812","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ackd.2017.05.006","article-title":"Kidney toxicities associated with novel cancer therapies.","volume":"24","author":"Lefebvre","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"R80-20230812","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: Single-center experience.","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R81-20230812","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4049\/jimmunol.1400497","article-title":"Both PD-1 ligands protect the kidney from ischemia reperfusion injury.","volume":"194","author":"Jaworska","year":"2015","journal-title":"J Immunol"},{"key":"R82-20230812","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy.","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"R83-20230812","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/annonc\/mdv136","article-title":"Renal effects of molecular targeted therapies in oncology: A review by the Cancer and the Kidney International Network (C-KIN).","volume":"26","author":"Launay-Vacher","year":"2015","journal-title":"Ann Oncol"},{"key":"R84-20230812","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"R85-20230812","first-page":"604","article-title":"Carfilzomib-related acute kidney injury.","volume":"11","author":"Jhaveri","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"R86-20230812","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3109\/10428194.2014.977887","article-title":"Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma.","volume":"56","author":"Chan","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R87-20230812","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective.","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit Care"},{"key":"R88-20230812","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1634\/theoncologist.2017-0055","article-title":"Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents.","volume":"22","author":"Cheson","year":"2017","journal-title":"Oncologist"},{"key":"R89-20230812","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","article-title":"Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: A systematic review.","volume":"95","author":"Howard","year":"2016","journal-title":"Ann Hematol"},{"key":"R90-20230812","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric antigen receptor T cell therapy and the kidney: What the nephrologist needs to know.","volume":"13","author":"Jhaveri","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"R91-20230812","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: Past, present and future.","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R92-20230812","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia.","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"R93-20230812","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbacli.2016.12.002","article-title":"Hemophagocytic lymphohistiocytosis in adults: An under recognized entity.","volume":"7","author":"Shah","year":"2017","journal-title":"BBA Clin"},{"key":"R94-20230812","doi-asserted-by":"crossref","first-page":"LBA6","DOI":"10.1182\/blood.V128.22.LBA-6.LBA-6","article-title":"Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): Results from the pivotal phase 2 zuma-1.","volume":"128","author":"Neelapu","year":"2016","journal-title":"Blood"},{"key":"R95-20230812","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the eye of the storm: Immune-mediated toxicities associated with CAR-T cell therapy.","volume":"3","author":"Garcia Borrega","year":"2019","journal-title":"HemaSphere"},{"key":"R96-20230812","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R97-20230812","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R98-20230812","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"},{"key":"R99-20230812","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"R100-20230812","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin Oncol"},{"key":"R101-20230812","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma.","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"R102-20230812","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial.","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"R103-20230812","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab.","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"R104-20230812","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma.","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"R105-20230812","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"R106-20230812","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"R107-20230812","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/17474086.2016.1183479","article-title":"Medical management of side effects related to CAR T cell therapy in hematologic malignancies.","volume":"9","author":"Namuduri","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"R108-20230812","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: Blinatumomab.","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"R109-20230812","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: An infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).","volume":"24","author":"Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R110-20230812","doi-asserted-by":"crossref","first-page":"e1040218","DOI":"10.1080\/2162402X.2015.1040218","article-title":"Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control.","volume":"4","author":"Arriola","year":"2015","journal-title":"Oncoimmunology"},{"key":"R111-20230812","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2051-1426-2-19","article-title":"Opportunistic infections in patients treated with immunotherapy for cancer.","volume":"2","author":"Kyi","year":"2014","journal-title":"J Immunother Cancer"},{"key":"R112-20230812","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11046-018-0291-4","article-title":"Invasive pulmonary aspergillosis complicated by carbapenem-resistant pseudomonas aeruginosa infection during pembrolizumab immunotherapy for metastatic lung adenocarcinoma: Case report and review of the literature.","volume":"184","author":"Oltolini","year":"2019","journal-title":"Mycopathologia"},{"key":"R113-20230812","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CJI.0000000000000081","article-title":"Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab.","volume":"38","author":"Uslu","year":"2015","journal-title":"J Immunother"},{"key":"R114-20230812","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma.","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R115-20230812","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology.","volume":"14","author":"Baden","year":"2016","journal-title":"J Natl Comp Canc Netw"},{"key":"R116-20230812","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.3748\/wjg.v20.i22.6716","article-title":"Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.","volume":"20","author":"Yazici","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R117-20230812","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM200101043440120","article-title":"Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.","volume":"344","author":"Dervite","year":"2001","journal-title":"N Engl J Med"},{"key":"R118-20230812","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"R119-20230812","first-page":"73","article-title":"Versatile CAR T-cells for cancer immunotherapy.","volume":"22","author":"Chu","year":"2018","journal-title":"Contemp Oncol (Pozn)"},{"key":"R120-20230812","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells.","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"key":"R121-20230812","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/hum.2018.180","article-title":"A cetuximab-mediated suicide system in chimeric antigen receptor-modified hematopoietic stem cells for cancer therapy.","volume":"30","author":"Kao","year":"2019","journal-title":"Hum Gene Ther"},{"key":"R122-20230812","doi-asserted-by":"crossref","first-page":"e0166891","DOI":"10.1371\/journal.pone.0166891","article-title":"In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia.","volume":"11","author":"Minagawa","year":"2016","journal-title":"PLoS One"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000004087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T05:06:20Z","timestamp":1691816780000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000004087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000004087","relation":{},"ISSN":["0090-3493"],"issn-type":[{"value":"0090-3493","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}